Core Insights - The pharmaceutical industry has seen a significant increase in merger and acquisition (M&A) activities since 2025, with 64 disclosed M&A events in A-shares, totaling approximately 110.38 billion yuan [1] - The trend indicates a dual-driven strategy of M&A and business development (BD) collaborations, focusing on enhancing innovation and filling gaps in capabilities [1][3] - The primary focus of M&A activities is on innovative drug research and development, medical services, and medical devices, reflecting a shift towards high-value sectors [1][2] M&A Trends - Pharmaceutical companies are increasingly acquiring near-commercial or mature technology platforms as a shortcut to catch up with technological advancements and address R&D shortcomings [2] - Notable M&A examples include Shijiazhuang Pharmaceutical's acquisition of a 29% stake in a biotech firm for 1.1 billion yuan and China Biologic's planned acquisition of 95.09% of a Shanghai-based company for 951 million USD [2] BD Collaborations - BD collaborations are also crucial for supplementing innovative drug pipelines, as seen in Changchun High-tech's partnership with ALK for allergy immunotherapy products [3] - Experts indicate that the current M&A and BD collaboration landscape is reshaping the industry, with a focus on building barriers in cutting-edge technologies like dual antibodies and ADCs [3] Industry Integration - The pharmaceutical industry is undergoing deeper integration, aiming to create a comprehensive closed-loop system encompassing R&D, production, and sales [4] - External collaborative M&A is a key pathway to achieving this closed-loop, as demonstrated by Chengdu Kanghua's acquisition aimed at enhancing its vaccine ecosystem [4] Capital Dynamics - The M&A landscape in 2025 is characterized by a multi-faceted capital structure, with leading companies taking the lead, supported by industry funds and flexible participation from social capital [6] - Leading firms are playing a stabilizing role, as seen in Beijing Tiantan's acquisition to enhance its plasma collection capabilities [6] Investment Strategies - Industry funds are exploring a "capital + BD" light asset model, with companies like Shanghai Fosun investing in innovative drug and medical device sectors [7] - Social capital is adopting a structured investment approach to empower innovation, focusing on AI medical applications and innovative drugs [7] Future Outlook - There is an expectation of continued capital investment in gene therapy, ADCs, and dual antibody platforms, indicating a sustained focus on high-value innovation areas [8]

Core Viewpoint - The company reported better-than-expected performance for 1H26FY, driven by strong growth in original prescription drugs, with revenue reaching 16.697 billion yuan, a year-on-year increase of 17.0% [1] Performance Review - For 1H26FY, the company achieved revenue of 16.697 billion yuan (+17.0% YoY) and non-GAAP net profit of 1.356 billion yuan (+38.7% YoY), with a profit margin of 8.1% (+1.3 percentage points YoY) [1] - Revenue breakdown by business segments shows self-operated business revenue at 14.38 billion yuan (+18.6% YoY), pharmaceutical e-commerce platform revenue at 1.84 billion yuan (+7.5% YoY), and digital service business revenue at 480 million yuan (+8.2% YoY) [1] Development Trends - The original prescription drug category is driving steady revenue growth for the company, with high growth in drug categories contributing to an increase in overall ARPU [1] - The company is enhancing strategic partnerships with upstream enterprises, including a strategic cooperation agreement with Innovent Biologics and a collaboration with Shengxiang Bio for a respiratory virus and bacteria testing project [2] Profitability Forecast and Valuation - The company is expected to maintain strong profitability, with an adjusted non-GAAP net profit forecast of 2.48 billion yuan and 2.75 billion yuan for the upcoming periods, reflecting a 16% increase [2] - The target price has been raised by 30% to 7.1 HKD, indicating a potential upside of 23%, while maintaining an outperform rating [2]

Core Viewpoint - The company has adjusted the grant price of the 2023 second phase restricted stock incentive plan from 8.55 yuan per share to 8.01 yuan per share, aligning the grant price of the reserved portion with the initial grant price [1][8][26]. Group 1: Decision-Making Process and Disclosure - The company held a board meeting on November 30, 2023, to approve the incentive plan and related proposals, with independent directors providing their opinions [2][14]. - The company disclosed the collection of proxy voting rights from shareholders for the upcoming general meeting on December 2, 2023 [3]. - The names and positions of the incentive plan participants were publicly announced from December 3 to December 12, 2023, with no objections received [4][15]. Group 2: Adjustment Reasons and Results - The adjustment in the grant price was necessitated by the company's capital distribution actions, including cash dividends of 2.75 yuan and 2.62 yuan per 10 shares, which required a corresponding adjustment to the grant price [6][8]. - The adjusted grant price calculation resulted in a new price of 8.01 yuan per share, ensuring it remains above the par value of the company's stock [8][9]. Group 3: Impact of the Adjustment - The adjustment of the grant price does not have a substantial impact on the company's financial status or operational results [9][19]. Group 4: Committee Opinions - The Compensation and Assessment Committee confirmed that the adjustment of the grant price was appropriate and complied with relevant regulations, ensuring no harm to the interests of the company and its shareholders [11][21]. Group 5: Legal Opinions - The legal opinion from Hunan Qiyuan Law Firm confirmed that the adjustments and actions taken regarding the incentive plan have received necessary approvals and comply with applicable laws and regulations [12][22].

证券代码：688289 证券简称：圣湘生物 公告编号：2025-074 圣湘生物科技股份有限公司 关于 2023 年第二期限制性股票激励计划首次授 予部分第一个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票拟归属数量：684,199 股 归属股票来源：圣湘生物科技股份有限公司（以下简称"公司"）从二级市场 回购的公司人民币 A 股普通股股票。 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划方案及履行的程序 1、本次股权激励计划主要内容 （1）股权激励方式：第二类限制性股票。 （2）授予数量：公司 2023 年第二期限制性股票激励计划（以下简称"本激励计 划"）授予的限制性股票总量为 800.00 万股，其中首次授予限制性股票 675.88 万股， 预留授予限制性股票 124.12 万股。 （3）授予价格（调整后）：8.01 元/股，首次授予价格与预留授予价格相同 （4）激励人数：首次授予 236 人，预留授予 56 人。 （5）具体的归属安排如下： 首次授予 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-075 圣湘生物科技股份有限公司 关于作废 2023 年第二期限制性股票激励计划部 分已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召开第三届 董事会 2025 年第五次临时会议，审议通过了《关于作废 2023 年第二期限制性股票激 励计划部分已授予尚未归属的限制性股票的议案》，现将相关事项公告如下： 一、本次限制性股票授予已履行的决策程序和信息披露情况 （一）2023 年 11 月 30 日，公司召开第二届董事会 2023 年第十二次临时会议， 会议审议通过了《关于<公司 2023 年第二期限制性股票激励计划（草案）>及其摘要 的议案》《关于<公司 2023 年第二期限制性股票激励计划实施考核管理办法>的议案》 以及《关于提请股东大会授权董事会办理公司限制性股票激励计划相关事宜的议案》 等议案。公司独立董事就本激励计划相关议案发表了独立意见。 ...

关于调整 2023 年第二期限制性股票激励计划授 予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召开第三届 董事会 2025 年第五次临时会议，审议通过了《关于调整 2023 年第二期限制性股票激 励计划授予价格的议案》，同意将公司 2023 年第二期限制性股票激励计划（以下简称 "本激励计划"）的授予价格由 8.55 元/股调整为 8.01 元/股，调整后，本激励计划预留 部分限制性股票授予价格与首次授予限制性股票的授予价格相同。 证券代码：688289 证券简称：圣湘生物 公告编号：2025-073 圣湘生物科技股份有限公司 现将有关事项说明如下： 一、本激励计划已履行的决策程序和信息披露情况 （一）2023 年 11 月 30 日，公司召开第二届董事会 2023 年第十二次临时会议， 会议审议通过了《关于<公司 2023 年第二期限制性股票激励计划（草案）>及其摘要 的议案》《关于<公司 2023 年第二期限制性股票激励计 ...

湖南启元律师事务所（以下简称"本所"）接受圣湘生物科技股份有限公司 （以下简称"公司""圣湘生物"）的委托，作为公司2023年第二期限制性股票 激励计划项目（以下简称"本次激励计划""激励计划"）专项法律顾问，为公 司本次激励计划提供专项法律服务。 2023 年第二期限制性股票激励计划调整授予价格、首 次授予部分第一个归属期符合归属条件及作废部分 限制性股票相关事项的法律意见书 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 2025 年 11 月 致：圣湘生物科技股份有限公司 湖南启元律师事务所 关于圣湘生物科技股份有限公司 （六）对于本所出具法律意见至关重要而又无法得到独立证据支持的事实， 本所根据公司、有关政府部门以及其他相关机构、组织或个人出具的证明出具意 见。对从国家机关、具有管理公共事务职能的组织、会计师事务所、资产评估机 构、资信评级机构、公证机构等独立第三方机构取得的证据资料，本所在履行一 般注意义务后，直接将其作为出具法律意见的依据。本所在法律意见中对 ...

董事会薪酬与考核委员会关于 2023 年第二期限制性 股票激励计划首次授予部分第一个归属期归属名单 的核查意见 圣湘生物科技股份有限公司 圣湘生物科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员会 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理 办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法 规及规范性文件和《圣湘生物科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，对公司 2023 年第二期限制性股票激励计划（以下简称"本激励计 划"）首次授予部分第一个归属期归属名单进行了核查，发表核查意见如下： 圣湘生物科技股份有限公司 董事会薪酬与考核委员会 2025 年 11 月 28 日 经核查，本激励计划首次授予的 236 名激励对象中，62 名激励对象因离职 已不再具备激励对象资格，1 名激励对象考核未达标，4 名激励对象因个人原因 自愿放弃本次归属。除上述不符合归属条件的 ...

第三届董事会 2025 年第五次临时会议决议公告 证券代码：688289 证券简称：圣湘生物 公告编号：2025-076 圣湘生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 圣湘生物科技股份有限公司（以下简称"公司"）第三届董事会 2025 年第五次 临时会议于 2025 年 11 月 28 日以现场结合通讯方式召开，会议通知已于 2025 年 11 月 25 日以邮件方式送达全体董事。会议由董事长戴立忠先生主持，应出席董事 11 人， 实际出席董事 11 人。会议的通知、召开及审议程序符合《中华人民共和国公司法》 （以下简称"《公司法》"）和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，一致通过如下议案： 1、审议通过了《关于调整 2023 年第二期限制性股票激励计划授予价格的议案》 内容：根据公司 2023 年第五次临时股东大会批准的公司 2023 年第二期限制性股 票激励计划（以下简称"本激励计划"），结合公司已实施的权益分派方案，董事会同 意将本激励 ...

Core Viewpoint - The market experienced mixed performance with the ChiNext index closing down 0.44%, while the influenza and organic silicon sectors surged, indicating a divergence in market sentiment driven by specific sectoral developments [1][4]. Group 1: Influenza Sector - The influenza sector saw a significant uptick, with flu-like cases in northern provinces rising to 7.0%, markedly higher than the same period in previous years [4]. - Sales of antiviral drugs, such as Oseltamivir, surged by 237% over the past week, indicating strong demand driven by rising flu cases [4]. - Jindike has completed the production season with 1.56 million doses of its quadrivalent flu vaccine approved for release, and is ramping up production capacity to 30 million doses [4]. Group 2: Organic Silicon Sector - The organic silicon sector experienced a boost following Dow Chemical's announcement of a 10%-20% price increase on major products starting December 10, which acted as a catalyst for domestic stocks [4]. - Companies like Hongbai New Materials and Chenguang New Materials saw their stocks hit the daily limit, while Dongyue Silicon Material rose over 10% [4]. - Smart money has already positioned itself in this sector, with Chenguang New Materials seeing a net inflow of 85.14 million yuan over the past ten trading days [4]. Group 3: Underperforming Sectors - The Hainan sector faced significant declines, with companies like Jingliang Holdings and Hainan Haiyao dropping nearly 7%, highlighting the lack of performance support for regional themes [4]. - The film and content industry also struggled, with Huanrui Century hitting the daily limit down and Shanghai Film falling nearly 7%, reflecting uncertainty in the content sector [4]. Group 4: Market Sentiment and Strategy - The overall trading volume decreased by 93.5 billion yuan compared to the previous day, indicating a cautious market sentiment and a tendency for rapid sector rotation [4]. - Investment strategies suggest focusing on the influenza sector for low-entry opportunities and the organic silicon sector for potential gains, while avoiding sectors lacking performance, policy support, or growth potential [5].